【火热】齐鲁制药拿下年年暴涨的潜力品种

米内网2025-07-15

精彩内容日前，齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评，成为公司今年以来获批的第15个品种。盐酸决奈达隆片是一种抗心律失常药物，近年来在中国三大终端六大市场（统计范围详见本文末）的销售额均以两位数及以上的增速持续增长。来源：米内网一键检索盐酸决奈达隆片是赛诺菲开发的一种抗心律失常药物，适用于有阵发性或持续性心房颤动病史的窦性心律患者，减少因心房颤动(AF)住院的风险。米内网数据显示...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2551157882?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-07-15 16:04","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2551157882","market":"hk","top_or_hot":-1,"title":"【火热】齐鲁制药拿下年年暴涨的潜力品种","media":"米内网","content":"<div>\n<p>精彩内容日前，齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评，成为公司今年以来获批的第15个品种。盐酸决奈达隆片是一种抗心律失常药物，近年来在中国三大终端六大市场（统计范围详见本文末）的销售额均以两位数及以上的增速持续增长。来源：米内网一键检索盐酸决奈达隆片是赛诺菲开发的一种抗心律失常药物，适用于有阵发性或持续性心房颤动病史的窦性心律患者，减少因心房颤动(AF)住院的风险。米内网数据显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715160717a6aa9717&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>【火热】齐鲁制药拿下年年暴涨的潜力品种</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n【火热】齐鲁制药拿下年年暴涨的潜力品种\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-07-15 16:04 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715160717a6aa9717&s=b><strong>米内网</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>精彩内容日前，齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评，成为公司今年以来获批的第15个品种。盐酸决奈达隆片是一种抗心律失常药物，近年来在中国三大终端六大市场（统计范围详见本文末）的销售额均以两位数及以上的增速持续增长。来源：米内网一键检索盐酸决奈达隆片是赛诺菲开发的一种抗心律失常药物，适用于有阵发性或持续性心房颤动病史的窦性心律患者，减少因心房颤动(AF)住院的风险。米内网数据显示...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715160717a6aa9717&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IE00B031HY20.USD","symbol_name":"FSSA CHINA GROWTH \"I\" (USD) INC","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715160717a6aa9717&s=b","article_id":"2551157882","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250715160717a6aa9717&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2551157882","pubTimestamp":1752566670,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"精彩内容日前，齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评，成为公司今年以来获批的第15个品种。盐酸决奈达隆片是齐鲁制药获批生产的首款抗心律失常药物。今年以来，齐鲁制药有15个品种获批生产并视同过评，包括4个全身用抗感染药物、4个消化系统及代谢药、3个抗肿瘤和免疫调节剂、2个心脑血管系统药物等。2025年以来齐鲁制药获批上市的品种来源：米内网中国申报进度数据库","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"IE00B031HY20.USD":"FSSA CHINA GROWTH \"I\" (USD) INC","LU1226288170.HKD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P6%\"(HK D) INC","LU1226287529.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) ACC","LU1226287875.USD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"PM\" (USD) INC","01477":"欧康维视生物-B","LU0880133367.SGD":"UBS (LUX) EQUITY FUND CHINA OPPORTUNITY USD \"P\" (SGD) ACC","01093":"石药集团","LU1226288253.USD":"UBS (LUX) KEY SELECTION SICAV - CHINA ALLOCATION  OPPORTUNITY (USD) \"P\" (USD) INC","BK1191":"制药","LU1951186391.HKD":"UBS (LUX) KEY SEL CHINA ALLOCATION OPPORTUNITY (US \"P\" (HKD) INC","IE00B5MMRT66.SGD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (SGDHDG) ACC","IE0008369823.USD":"FSSA HONG KONG GROWTH \"I\" ACC","LU1152091168.USD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" INC","LU1993786604.SGD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (SGD) ACC","LU1807302812.USD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (USD) ACC","LU1226287792.SGD":"UBS (LUX) KEY SEL S-CHINA ALLOCATION OPP \"P\" (SGDHDG) INC","LU1960683339.HKD":"UBS (LUX) EQUITY SICAV ALL CHINA \"P\" (HKD) ACC","IE00BZ08YR35.GBP":"GUINNESS BEST OF CHINA \"C\" (GBP) ACC","LU0140636845.USD":"施罗德大中华区股票A Acc","BK1515":"抗疫概念","LU0501845795.SGD":"瑞银大中华区股票基金P Acc SGD","LU0315179316.USD":"EASTSPRING INVESTMENTS ASIAN DYNAMIC \"A\" (USD) ACC","BK1574":"生物医药B类股","LU0067412154.USD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (USD) ACC","IE00BZ08YS42.EUR":"GUINNESS BEST OF CHINA \"C\" (EUR) ACC","LU0072913022.USD":"UBS (LUX) EQUITY FUND -  GREATER CHINA \"P\" (USD) ACC","LU1152091754.HKD":"UBS (LUX) EQUITY FUND - CHINA OPPORTUNITY (USD) \"PM\" (HKD) INC","IE00BZ08YT58.USD":"GUINNESS BEST OF CHINA \"C\" (USD) ACC","LU1008478684.HKD":"UBS (LUX) EQUITY FUND -  CHINA OPPORTUNITY \"P\" (HKD) ACC","SG9999004220.SGD":"Nikko AM Shenton Asia Dividend Equity Fund  SGD","BK1521":"挪威政府全球养老基金持仓","IE00B543WZ88.USD":"NEUBERGER BERMAN CHINA EQUITY \"A\" (USD) ACC","IE0008368742.USD":"首域中国增长基金I Acc","LU0326950275.SGD":"Schroder ISF China Opportunities A Acc SGD-H"},"translate_title":"[Hot] Qilu Pharmaceutical wins the potential varieties that are skyrocketing every year","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01093":0.9,"01477":1},"content_text":"精彩内容日前，齐鲁制药申报的4类仿制药盐酸决奈达隆片获批生产并视同过评，成为公司今年以来获批的第15个品种。盐酸决奈达隆片是一种抗心律失常药物，近年来在中国三大终端六大市场（统计范围详见本文末）的销售额均以两位数及以上的增速持续增长。来源：米内网一键检索盐酸决奈达隆片是赛诺菲开发的一种抗心律失常药物，适用于有阵发性或持续性心房颤动病史的窦性心律患者，减少因心房颤动(AF)住院的风险。米内网数据显示，近年来盐酸决奈达隆片在中国三大终端六大市场的销售额均以两位数及以上的增速持续增长，2024年超过1.4亿元，2025第一季度以约38%的增速继续增长。近年来中国三大终端六大市场盐酸决奈达隆片销售情况（单位：万元）来源：米内网格局数据库目前有6家药企的盐酸决奈达隆片过评或视同过评，包括石药集团、江苏利泰尔药业、鲁南制药、青峰医药、石家庄四药及齐鲁制药，该产品已满足国采入围门槛；此外，安徽艾立德制药的产品以新注册分类报产在审。盐酸决奈达隆片是齐鲁制药获批生产的首款抗心律失常药物。米内网数据显示，2024年中国三大终端六大市场抗心律失常药（Ⅰ型和Ⅲ型）销售额超过8亿元。产品排名中，盐酸决奈达隆片由2023年的第4位提升至2025第一季度的第2位。今年以来，齐鲁制药有15个品种获批生产并视同过评，包括4个全身用抗感染药物、4个消化系统及代谢药、3个抗肿瘤和免疫调节剂、2个心脑血管系统药物等。2025年以来齐鲁制药获批上市的品种来源：米内网中国申报进度（MED）数据库","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2551157882","isCrawlerRequest":true}